Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00193466
Phase
PHASE2
Status
Completed

Conditions

  • Non-Hodgkins Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
  • Fludarabine — DRUG
  • CAMPTH-1H — DRUG

Study Details

In this multicenter trial, we will investigate the use of fludarabine plus rituximab, followed by Campath-1H, in previously untreated patients with CLL/SLL. Patients who are elderly, or who are considered unlikely to tolerate this combination therapy well, will receive single agent rituximab followed by Campath-1H.

Key Dates

First listed
Sep 19, 2005
Start date
Jan 31, 2002
Status verified
Dec 2010
Primary completion
Jan 31, 2007
Completion
Apr 30, 2008

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Complete response rate

Related Studies